Clinical effect of efgartigimod in treatment of severe anti-N-methyl-D-aspartate receptor encephalitis comorbid with myelin oligodendrocyte glycoprotein antibody-associated disorders： A case report and literature review
10.19845/j.cnki.zfysjjbzz.2025.0052
- VernacularTitle:艾加莫德治疗复发的重症抗NMDAR脑炎合并MOGAD 1例报告
- Author:
Jing DU
1
Author Information
1. Department of Neurology， The Second Affiliated Hospital of Anhui Medical University， Hefei 230601， China
- Publication Type:Journal Article
- Keywords:
Anti-N-methyl-D-aspartate receptor encephalitis;
Myelin oligodendrocyte glycoprotein antibody-associated disorders
- From:
Journal of Apoplexy and Nervous Diseases
2025;42(3):258-261
- CountryChina
- Language:Chinese
-
Abstract:
This article reports the clinical features and prognosis of a patient with severe recurrent anti-N-methyl-D-aspartate receptor encephalitis comorbid with myelin oligodendrocyte glycoprotein antibody-associated disorders （MOGAD） who was treated with efgartigimod. Neuroimmune overlap syndrome has complex clinical manifestations， and the novel FcRn antagonist efgartigimod may be effective in patients who do not respond well to first-line treatment.
- Full text:2025071610391029057艾加莫德治疗复发的重症抗NMDAR脑炎合并MOGAD 1例报告.pdf
